KMDA (Kamada) Inventories, Raw Materials & Components : $0.0 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Kamada Inventories, Raw Materials & Components?

Kamada's inventories, raw materials & components for the quarter that ended in Sep. 2024 was $0.0 Mil.

Kamada's annual raw materials increased from Dec. 2021 ($16.8 Mil) to Dec. 2022 ($21.3 Mil) and increased from Dec. 2022 ($21.3 Mil) to Dec. 2023 ($28.3 Mil).

Kamada Inventories, Raw Materials & Components Historical Data

The historical data trend for Kamada's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Inventories, Raw Materials & Components Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

11.70

13.42

16.82

21.33

28.28

Kamada Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															-	28.28	-	-	-

Kamada Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Kamada Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.